SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 ...
FDA Approves PD-L1 Companion Diagnostic in Triple-Negative Breast Cancer This past Friday, Agilent Technologies announced it has received approval by the FDA for the use of PD-L1 IHC 22C3 pharmDx as ...
Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. This is an ASCO Meeting ...
PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations Four programmed death ligand 1 (PD-L1) immunohistochemistry assays (28-8, 22C3, SP263, and SP142) have been approved ...
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests to improve the management of cancer patients, announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results